DOI QR코드

DOI QR Code

Antihyperlipidemic Effects of Red Ginseng, Crataegii Fructus and Their Main Constituents Ginsenoside Rg3 and Ursolic Acid in Mice

  • Published : 2008.12.31

Abstract

Anti-hyperlipidemic effect of red ginseng (RG; the steamed root of Panax ginseng C.A. Meyer) and Crataegii fructus (CF, the fruit of Crataegus pinnatifida BGE), which are used frequently in China and Korea as herbal medicines to treat arteriosclerosis, were investigated. Treatments of RG and CF significantly reduced blood triglyceride (TG) and total cholesterol (TC) levels in Triton WR-1339-induced hyperlipidemic mice and serum TG levels in corn oil-induced hypertriglyceridemic mice. Ginsenoside Rg3 and ursolic acid, the main constituents of RG and CF, respectively, also reduced TG and TC levels in hyperlipidemic mice. RG and CF significantly lowered the high blood TG and TC levels and body and epididymal mass weights induced by long-term feeding of a high-fat diet and increased the high-fat diet-induced decrease in blood HDL cholesterol levels. RG and Rg3 reduced the blood TC levels more than CF and ursolic acid. However, blood TG level were reduced by CF and ursolic acid more than RG and Rg3. RG, CF, and their constituents also inhibited pancreatic lipase and HMG-CoA reductase activities. The most potent inhibitor was Rg3. These findings suggest that RG and CF may be suitable for the therapies of hypercholesterolemia and triglyceridemia, respectively.

References

  1. Allain, C. C., Poon, L. S., Chan, C. S. G., Richmond, W. and Fu, P. C.(1974). Enzymatic determination of total serum cholesterol. Clin. Chem. 20, 470-475
  2. Bae, E. A., Han, M. J., Choo, M. K., Park, S. Y. and Kim, D. H.(2002). Metabolism of 20(S)- and 20(R)-ginsenoside Rg3 by human intestinal bacteria and its relation to in vitro biological activities. Biol. Pharm. Bull. 25, 58-63 https://doi.org/10.1248/bpb.25.58
  3. Ballinger, A. (2000). Orlistat in the treatment of obesity. Expert. Opin. Pharmacother. 1, 841-847 https://doi.org/10.1517/14656566.1.4.841
  4. Birari, R. B. and Bhutani, K. K. (2007). Pancreatic lipase inhibitors from natural sources: unexplored potential. Drug Discovery Today 12, 879-889 https://doi.org/10.1016/j.drudis.2007.07.024
  5. Carey, M. C., Small, D. M. and Bliss, C. M. (1993). Lipid digestion and absorption. Annu. Rev. Physiol. 45, 651-677 https://doi.org/10.1146/annurev.ph.45.030183.003251
  6. Chang, W. T., Dao, J., Shao, Z. H. (2005). Hawthorn: potential roles in cardiovascular disease. Am. J. Chin. Med. 33, 1-10 https://doi.org/10.1142/S0192415X05002606
  7. Davidson, M. H. (2003). Ezetimibe: a novel option for lowering cholesterol. Expert. Rev. Cardiovasc. Ther. 1, 11-21 https://doi.org/10.1586/14779072.1.1.11
  8. Duhault, J., Boulanger, M., Beregi, L., Sicot, N., Bouvier, F. (1976). 780 SE: a new type of hypolipemic agent. Atherosclerosis, 23, 63-72 https://doi.org/10.1016/0021-9150(76)90118-0
  9. Edwards, P. A., Lemongello, D. and Fogelman, A. M. (1979). Improved methods for the solubilization and assay of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase. J. Lipid Res. 20, 40-46
  10. Edwards, P. A., Lemongello, D. and Kane, J. (1980). Properties of purified rat hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase and regulation of enzyme activity. J. Biol. Chem. 255, 3715-3725
  11. Endo, A. (1992). The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 33, 1569-1582
  12. Espenshade P. J., Hughes A. L. (2007). Regulation of sterol synthesis in eukaryotes. Annu. Rev. Genet. 41, 401-427 https://doi.org/10.1146/annurev.genet.41.110306.130315
  13. Goldstein, J. L., Schrott, H., Hazzard, E., Bierman, E. and Motuski, A. (1973). Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. J. Clin. Invest. 52, 1544-1568 https://doi.org/10.1172/JCI107331
  14. Heber, D. (2001). Herbs and atherosclerosis. Curr. Atheroscler. Rep. 3, 93-96 https://doi.org/10.1007/s11883-001-0016-9
  15. Heller, R. A. and Shrewsburg, M. A. (1976). 3-Hydroxy-3-methylglutaryl coenzyme A reductase from rat liver. Its purification, properties, and immunochemical studies. J. Biol. Chem. 251, 3815-3822
  16. Ia Cour, B., Molgaard, P., Yi, Z. (1995). Traditional Chinese medicine in treatment of hyperlipidaemia. J. Ethnopharmacol. 46, 125-129 (1995) https://doi.org/10.1016/0378-8741(95)01234-5
  17. Inoue, M., Wu C.Z., Dou D.Q., Chen Y.J., Ogihara Y. (1999). Lipoprotein lipase activation by red ginseng saponins in hyperlipidemia model animals. Phytomedicine 6, 257-265 https://doi.org/10.1016/S0944-7113(99)80018-X
  18. Kim H. Y., Jeong da, M., Jung, H. J., Jung, Y. J., Yokozawa, T. and Choi, J. S. (2008). Hypolipidemic effects of Sophora flavescens and its constituents in poloxamer 407-induced hyperlipidemic and cholesterol-fed rats. Biol. Pharm. Bull. 31, 73-78 https://doi.org/10.1248/bpb.31.73
  19. Liu, J. (1995). Pharmacology of oleanolic acid and ursolic acid. J. Ethnopharmacol. 49, 57-68 https://doi.org/10.1016/0378-8741(95)90032-2
  20. Meigs, T. E., Roseman, D. S. and Simoni, R. D. (1996). Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo. J. Biol. Chem. 271, 7916-7922 https://doi.org/10.1074/jbc.271.14.7916
  21. Thomson, A. B., Schoeller, C., Keelan, M., Smith, L. Clandinin M. T. (1993). Lipid absorption: passing through the unstirred layers, brush-border membrane, and beyond. Can. J. Physiol. Pharmacol. 71, 531-555 https://doi.org/10.1139/y93-078
  22. Thompson Coon J. S. and Ernst E. (2003). Herbs for serum cholesterol reduction: a systematic view. J. Fam. Pract. 52, 468-478
  23. Trinh, H. T., Han, S. J., Kim, S. W., Lee, Y. C. and Kim, H. D. (2007). Bifidus fermentation increases hypolipidemic and hypoglycemic effects of red ginseng. J. Microbiol. Biotechnol. 17, 1127-1133
  24. White, L. W. and Rudney, H. (1970). Regulation of 3-hydroxy-3-methylglutarate and mevalonate biosynthesis by rat liver homogenates. Effects of fasting, cholesterol feeding, and triton administration. Biochemistry 9, 2725-2731 https://doi.org/10.1021/bi00815a021
  25. Zhou, L., Zuo, Z. and Chow, M. S. (2005). Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J. Clin. Pharmacol. 45, 1345-1359 https://doi.org/10.1177/0091270005282630
  26. Kusama, H., Nishiyama, M. and Ikeda, S. (1988). Pharmacological investigation of bezafibrate, a hypolipidemic agent (1). Effects of bezafibrate on normal and experimental hyperlipidemia in rats. Folia Pharmacol. Jpn. 92, 175-180 https://doi.org/10.1254/fpj.92.175
  27. Sardesai V.M. and Mannig J.A., The determination of triglycerides in plasma and tissues. Clin. Chem. 14, 156-158

Cited by

  1. Evaluation of aCrataegus-Based Multiherb Formula for Dyslipidemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial vol.2014, 2014, https://doi.org/10.1155/2014/365742
  2. Triterpenoids from Cyclocarya paliurus and their inhibitory effect on the secretion of apoliprotein B48 in Caco-2 cells vol.142, 2017, https://doi.org/10.1016/j.phytochem.2017.06.015
  3. Anti-hyperlipidemic Effects of Red Ginseng Acidic Polysaccharide from Korean Red Ginseng vol.33, pp.3, 2010, https://doi.org/10.1248/bpb.33.468
  4. Effects of various ginsenosides and ginseng root and ginseng berry on the activity of Pancreatic lipase vol.26, pp.3, 2017, https://doi.org/10.1007/s10068-017-0090-6
  5. Microbial transformation of ursolic acid by Syncephalastrum racemosum (Cohn) Schroter AS 3.264 vol.82, 2012, https://doi.org/10.1016/j.phytochem.2012.06.020
  6. Anti-lipase and lipolytic activities of ursolic acid isolated from the roots of Actinidia arguta vol.32, pp.7, 2009, https://doi.org/10.1007/s12272-009-1702-3
  7. Estrogen Receptor Is Activated by Korean Red Ginseng In Vitro but Not In Vivo vol.36, pp.2, 2012, https://doi.org/10.5142/jgr.2012.36.2.169
  8. Polyphenolic Profile and Biological Activity of Chinese Hawthorn (Crataegus pinnatifida BUNGE) Fruits vol.17, pp.12, 2012, https://doi.org/10.3390/molecules171214490